New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 29, 2013
19:00 EDTCRM, BEBE, PSUN, OVTI, KKD, CLNE, NUAN, MITL, SPLK, APRIOn The Fly: After Hours Movers
UP AFTER EARNINGS: salesforce.com (CRM), up 8.4%... Splunk (SPLK), up 6.5%... Mitel (MITL), up 5%. ALSO HIGHER: Nuance (NUAN), up 0.6% after Carl Icahn disclosed a 16.9% stake in the company and saying he may seek talks with the company regarding a seat on its board... Clean Energy (CLNE), up 1.2% after announcing that a subsidiary of the company signed a three-year compressor supply agreement with a potential value up to $167M. DOWN AFTER EARNINGS: Krispy Kreme (KKD), down 12.8%.... OmniVision (OVTI), down 9.7%... Pacific Sunwear (PSUN), down 9.4%... bebe stores (BEBE), down 4%. ALSO LOWER: Apricus Biosciences (APRI), down 2.9% after announcing that Swissmedic recommended against approval of marketing authorization for its Vitaros erectile dysfunction treatment.
News For CRM;SPLK;MITL;NUAN;CLNE;KKD;OVTI;PSUN;BEBE;APRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
08:03 EDTMITLMitel proposes to acquire ShoreTel for $8.10 per share in cash
06:13 EDTAPRIApricus Biosciences to host conference call
Subscribe for More Information
05:49 EDTNUANStocks with implied volatility movement; TLM NUAN
Subscribe for More Information
05:27 EDTAPRIApricus licensed U.S. development, commercialization rights for fispemifene
Apricus Biosciences announced that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator, or SERM, fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland. This license agreement combines Apricus' expertise in men's health with Forendo's established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for urological conditions in men. Under the terms of the agreement, Forendo and its advisors received an upfront license fee of $12.5M comprised of a $5M cash payment and the issuance of $7.5M in Apricus common stock; approximately 3.6M shares priced at the 360-day average market price of $2.08 per share. The agreement includes additional potential clinical and regulatory milestone payments to Forendo of up to $45M, including for potential FDA approval, as well as potential commercial milestone payments totaling up to $260M, based on achieving specified annual net sales levels up to $1B in the U.S. Apricus will also pay tiered low double-digit royalties based on net sales once the product is commercialized. Apricus will be responsible for the clinical development of fispemifene in the U.S., as well as all future commercialization efforts in the U.S. and its territories.
October 17, 2014
10:00 EDTCLNEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:44 EDTCRMSalesforce.com moving in right direction in every way, says Canaccord
Subscribe for More Information
06:09 EDTCLNEClean Energy initiated with a Hold at MLV & Co.
Target $8.
October 16, 2014
07:57 EDTCRMSalesforce president lays out vision for quadrupling revenue, WSJ reports
Salesforce (CRM) president and vice chairman Keith Block outlined his plan to grow the company's annual revenue to $20B at the company’s annual Dreamforce conference, said The Wall Street Journal, which noted that Block specifically said, “We want to be bigger than SAP.” Block's strategy involves expansion in new product areas, adding new packages of software tailored to a handful of high-value industries, and expanding sales efforts outside of North America, the Journal reported. Reference Link
October 15, 2014
13:14 EDTNUANNuance upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
06:02 EDTCLNEClean Energy delivers 50.6M CNG gallons in Q3
Clean Energy reported it delivered for the first time over 50M compressed natural gas gallons in one quarter. The company plans to grow its CNG sales further with a strategic move to expand its CNG market to large industrial and institutional energy users beyond the nation’s natural gas pipeline by acquiring a controlling interest in NG Advantage, a pioneer in the natural gas “virtual pipeline” delivery system. The NG Advantage investment will primarily be used to fund capital expenditures for expansion and growth in the business. Clean Energy will also purchase NG Advantage’s Milton, Vt., compression station which is on track to supply nearly 16M gasoline-gallon-equivalents of CNG annually. This station will immediately become Clean Energy’s highest-volume station in its nationwide network of almost 500 stations.
October 13, 2014
16:33 EDTCRMMicrosoft and Salesforce.com unveil new joint solutions
Subscribe for More Information
14:35 EDTCRMSalesforce launches analytics cloud
Salesforce earlier today announced Wave, Salesforce Analytics Cloud. Wave is the first cloud analytics platform designed for every business user, making it easier than ever for anyone to explore data, uncover new insights and take action instantly from any device, the company stated. Companies can now quickly deploy sales, service and marketing analytics, or build custom mobile analytics apps, using any data source, Salesforce added.
10:43 EDTCRMSalesforce.com October volatility elevated into executive Q&A with Marc Benioff
Subscribe for More Information
09:23 EDTSPLKHP could buy lower valuation company, says Bernstein
Subscribe for More Information
07:38 EDTCRMSalesforce to hold a conference
Dreamforce 2014 is being held in San Francisco on October 13-16.
07:13 EDTAPRIApricus Biosciences awarded U.S. patent for RayVa
Apricus Biosciences announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/110,348. The patent application generally is directed to methods and compositions for treating Raynaud's phenomenon, including claims related to treating Raynaud's phenomenon that is secondary to systemic sclerosis. Raynaud's phenomenon secondary to systemic sclerosis affects an estimated three to five percent of people in the U.S., disproportionately affecting women and currently has no approved therapy in the U.S., representing an unmet medical need. The FDA has indicated that Apricus' RayVa™ product may qualify for priority review, given the unmet medical need and lack of approved products to treat secondary Raynaud's phenomenon. The FDA will determine if the RayVa New Drug Application qualifies for priority review following its submission, which could occur as early as 2017.
06:04 EDTSPLKSplunk upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Splunk to Outperform citing better earnings visibility and more reasonable valuation levels.
October 12, 2014
17:20 EDTCRM, SPLKGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information
October 10, 2014
07:23 EDTSPLKSplunk price target raised to $65 from $56 at Deutsche Bank
Subscribe for More Information
October 9, 2014
07:34 EDTCRMSalesforce.com coverage assumed with a Buy at MKM Partners
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use